Cytosorbents (CTSO) Q4 2024 earnings summary

Executive summary

• Achieved 15% year-over-year growth in core product revenue to $35.6M for 2024, with Q4 product revenue up 25% to $9.2M; gross margin held at 71% for both periods.

• Growth driven by strong direct sales outside Germany (up 28%) and distributor/partner sales (up 22%), while German sales remained flat for the second year.

• Regulatory submissions for DrugSorb-ATR made to FDA and Health Canada; decisions expected in 2025, with commercialization plans and controlled launch preparations underway.

• Strengthened balance sheet through a $20M debt facility, $7.3M rights offering, and warrant exercise, increasing net liquidity by $12.3M and supporting future growth initiatives.

• Expanded clinical portfolio with new data and presentations supporting CytoSorb and DrugSorb-ATR efficacy in cardiac surgery and critical care.

Financial highlights

• Q4 2024 product revenue: $9.2M (+25% YoY); full-year 2024 product revenue: $35.6M (+15% YoY); total revenue (historical convention): $39.2M (+8%).

• Gross margin for Q4 and full year: 71%, up from 68% in Q4 2023.

• Q4 operating expenses down 30% YoY to $10.2M; Q4 operating loss improved 61% YoY to $3.7M; full-year operating loss improved 47% to $16.7M.

• Adjusted EBITDA loss for Q4 improved by 70% to $2.4M; full-year adjusted EBITDA loss improved by 56% to $11.5M.

• Adjusted net loss for 2024: $12.7M ($0.23/share), improved from $27M ($0.61/share) in 2023.

Outlook and guidance

• Targeting near cash flow break-even in core business by end of 2025, excluding DrugSorb-ATR revenues.

• Expecting short-term disruption and modestly lower product sales in Q1 2025 due to German sales team reorganization, but anticipate growth in Germany and overall in the second half of 2025.

• Confident in capital position to support DrugSorb-ATR launch and operations into 2026.

• Regulatory decisions for DrugSorb-ATR in the US and Canada expected in 2025, with controlled market release planned upon approval.